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Abstract
Capmatinib is an oral, ATP-competitive, and highly potent, type 1b MET inhibitor. 
Herein, we report phase 1 dose-escalation results for capmatinib in advanced MET-
positive solid tumor patients and dose expansion in advanced non-lung tumors. 
Capmatinib was well tolerated with a manageable safety profile across all explored 
doses. Dose-limiting toxicities (DLT) occurred at 200 mg twice daily (bid), 250 mg bid, 
and 450 mg bid capsules; however, no DLT were reported at 600 mg bid (capsules). 
Capmatinib tablets at 400 mg bid had comparable tolerability and exposure to that of 
600 mg bid capsules. Maximum tolerated dose was not reached; recommended phase 
2 dose was 400 mg bid tablets/600 mg bid capsules; at this dose, Ctrough >EC90 (90% 
inhibition of c-MET phosphorylation in animal models) is expected to be achieved 
and maintained. Among the dose-expansion patients (N = 38), best overall response 
across all cohorts was stable disease (gastric cancer 22%, hepatocellular carcinoma 
46%, other indications 28%); two other indication patients with gene copy number 
(GCN) ≥6 achieved substantial tumor reduction. Near-complete immunohistochemi-
cally determined phospho-MET inhibition (H-score = 2) was shown following cap-
matinib 450 mg bid capsule in paired biopsies obtained from one advanced colorectal 
cancer patient. Incidence of high-level MET GCN (GCN ≥6) and MET-overexpressing 
(immunohistochemistry 3+) tumors in the expansion cohorts was 8% and 13%, re-
spectively; no MET mutations were observed. Thus, the recommended phase 2 dose 
(RP2D) of capmatinib was 600 mg bid capsule/400 mg bid tablet. Capmatinib was 
well tolerated and showed antitumor activity and acceptable safety profile at the 
RP2D.
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1  | INTRODUC TION
Dysregulation of MET signaling leads to activation of downstream 
pathways that include the RAS/MAPK, PI3K/AKT, and Rac/Rho 
pathways, promoting cell proliferation, survival, and metastasis.1 
MET dysregulation, through gene amplification, mutation, and/or 
overexpression has been described in multiple tumor types, includ-
ing lung, HCC, GBM, pRCC, breast, colon, and gastric cancers.1
High-level MET gene amplification was originally described in 
gastric cancer cell lines,2 resulting in increased mRNA and protein 
overexpression.3 In EGFRwt, NSCLC de novo MET amplification has 
been reported in 1% to 4% of newly diagnosed cases.4-6 MET am-
plification is also implicated in the acquired resistance to EGFR TKI, 
reported in 5% to 26% of cases, regardless of the presence of the 
T790M mutation.7-13
In addition, MET mutations have been identified in primary tu-
mors as well as in metastatic lesions of several cancers, including 
head and neck, pRCC, liver, ovarian, and NSCLC.14,15 In NSCLC, 
splice site alterations at exon 14 that lead to reduced internalization 
and degradation and net overexpression occur in 2% to 3% of adeno-
carcinomas16-19 and in up to 22% of sarcomatoid NSCLC.20
Elevated levels of the receptor ligand HGF and/or overexpres-
sion of MET is often associated with resistance to chemotherapy and 
radiotherapy.21 Overall, MET dysregulation is recognized as a nega-
tive prognostic factor, especially in advanced NSCLC22-24 and is also 
associated with poor clinical outcomes in patients with glioblastoma 
and squamous cell carcinoma of the head and neck.25,26
Several MET inhibitors, comprising small molecule TKI and 
mAb targeting MET or its ligand, HGF, have been developed.27 
TKI are mainly divided into three types (I, II, and III) depending on 
binding of ATP to the MET kinase domain.28,29 The apo-MET ki-
nase adopts a distinctive autoinhibitory conformation (activation 
loop locks into the ATP binding site through a salt bridge between 
D1228 and K1110). Type I MET inhibitors are ATP-competitive, 
and bind to MET unique autoinhibitory conformation (π-stacking 
with Y1230 in the MET activation loop). Type I inhibitors are fur-
ther divided into type Ia and type Ib. Potency of type Ia inhibi-
tors is due to interaction with Y1230, the hinge, and the solvent 
front glycine residue G1163 (analogous to the same position as 
ALK G1202 and ROS1 G2032), whereas type Ib MET inhibitors 
have stronger interactions with Y1230 and the hinge, but not with 
G1163. Thus, type Ib inhibitors are highly specific for MET with 
fewer off-target effects compared with type Ia inhibitors. Type II 
inhibitors are ATP-competitive, but bind to the ATP adenine bind-
ing site extending to the hydrophobic back pocket. They distort 
the apo-MET autoinhibitory conformation and bind to an induced 
conformation. They do not have interaction with G1163. Type III 
inhibitors bind to allosteric sites different from the ATP binding 
site.28 Capmatinib (INC280) is an oral, ATP-competitive and highly 
potent type 1b MET inhibitor in biochemical (IC50 0.13 nmol/L) 
and cellular (IC50 ~ 1 nmol/L) assays and has proven to be highly 
selective versus other kinases in large panels of biochemical 
and binding assays.30,31 Capmatinib caused regression of MET-
dependent tumors at tolerable doses in animal models across a 
range of tumor types, including NSCLC, HCC, and GBM.30,31 MET 
dependency in such responsive tumor models was associated with 
MET gene amplification (NSCLC, HCC), MET exon 14 skipping mu-
tation (NSCLC), marked MET overexpression without amplifica-
tion (NSCLC), or coexpression of MET and its ligand HGF (GBM).
The present phase 1 dose-escalation study (NCT01324479) as-
sessed the safety and tolerability of capmatinib in patients with ad-
vanced MET-positive solid tumors. We also report herein the safety 
and efficacy observed in expansion cohorts of patients with MET-
dysregulated gastric cancer, HCC, and other tumors (including GBM 
and pRCC). Safety and efficacy results of the expansion cohort of 
patients with advanced NSCLC is reported separately (Schuler M et 
al; manuscript submitted).
2  | MATERIAL S AND METHODS
2.1 | Study design and treatment
This was a phase 1, open-label, multicenter, nonrandomized, two-
part study comprising dose-escalation and expansion parts in-
cluding patients with gastric cancer, HCC, and other solid tumor 
indications. In the first part of the study, molecularly prescreened 
patients with MET-dysregulated advanced solid tumors were en-
rolled in the dose-escalation phase. In the expansion phase, pa-
tients with solid tumors, including NSCLC, were enrolled based on 
MET dysregulation. Later, an additional expansion group was imple-
mented to enrol patients with EGFRwt NSCLC preselected centrally 
(ClinicalTrials.gov Identifier: NCT01324479).
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based on a high MET expression (IHC score 3+); results for the origi-
nal NSCLC expansion group and additional expansion group are re-
ported separately (Schuler M et al; manuscript submitted).
The primary objective of the present study was to determine the 
MTD/RP2D of oral capmatinib based on the incidence, frequency, and 
category of DLT in cycle 1 and the AE. A two-parameter BLRM using 
the EWOC principle32,33 was used to guide the dose escalation for de-
termination of the MTD or RP2D. Dose escalation was based on the 
incidence of DLT during cycle 1, with additional analyses carried out 
if significant toxicities were observed during later cycles (criteria for 
DLT provided in Table S1). After completion of a given cohort, the deci-
sion to dose escalate and the actual dose chosen depended on risk as-
sessment calculations using the BLRM and medical review of available 
clinical and laboratory data, and the BLRM estimated the MTD by up-
dating estimates of the probability of observing a DLT in the first cycle. 
For a given schedule, the MTD was defined as the highest drug dosage 
not expected to lead to DLT in >33% of patients in the first 28 days.
The key secondary endpoint was ORR by investigator assessment, 
defined as the proportion of subjects with measurable disease whose 
best overall response is either complete response or partial response 
according to the RECIST v1.1 or MacDonald criteria (only for GBM). 
Other secondary objectives were to further characterize antitumor 
activity, safety and tolerability, PK and PD (paired biopsies; IHC of 
p-MET, phospho-ERK, phospho-AKT, and phospho-S6, PK parame-
ters), and DCR (proportion of patients whose best overall response is 
either complete response or partial response or stable disease).
In the dose-escalation part, separate cohorts of patients received 
treatment with increasing doses of capmatinib, starting at 100 mg 
bid in capsule formulation. PK and safety data from a tablet safety 
cohort were also used to guide the calculation of a tablet dose that 
would achieve comparable exposure to that of the RP2D of capmati-
nib capsules and meet the EWOC criteria in the BLRM for tablet. In the 
dose-expansion cohorts, patients were treated at a capmatinib dose of 
600 mg bid, which is the RP2D of capmatinib capsules as determined 
in the safety cohort. Patients were permitted to switch to the 400 mg 
bid tablet dose. Patients were treated in 28-day cycles provided there 
was no evidence of disease progression or excessive toxicity and were 
continually reassessed for evidence of acute and cumulative toxicity.
2.2 | Patients
Adult patients (aged ≥18 years) with advanced solid tumors that are 
refractory to currently available therapies or for whom no effective 
treatment is available were eligible. Patients were required to have 
an ECOG Performance Status ≤2 and locally or centrally confirmed 
MET dysregulation as follows: for NSCLC, nasopharyngeal cancer, 
triple-negative breast cancer, pRCC, gastric cancer, and any other 
type of solid tumor, a MET H-score ≥150 or a ratio of MET/cen-
tromere ≥2.0 or MET GCN ≥5, or ≥50% of tumor cells with IHC score 
2+ or score 3+; for HCC and GBM, a MET H-score ≥50 or a ratio 
of MET/centromere ≥2.0 or MET GCN ≥5. Patients with pRCC and 
germline MET mutation (in local report) were eligible. Key exclusion 
criteria were symptomatic CNS metastases that are neurologically 
unstable or requiring increasing doses of steroids to control; prior 
therapy with MET inhibitors or HGF-targeted therapy; or any CNS 
deficits (for GBM, CNS symptoms grade 2 or greater).
2.3 | Clinical assessments
Tumor lesions were assessed according to the RECIST v1.0 (inves-
tigator confirmed) or MacDonald criteria for patients with GBM. 
CT-based tumor assessments were carried out unless contraindi-
cated or for GBM, in which case MRI with contrast was carried out. 
Assessments were carried out at screening, every 8 weeks beginning 
at the start of cycle 3 and as required to confirm response, and at 
the end of treatment (if no scan within 30 days prior to end of treat-
ment). Safety assessments were carried out based on all AE, clinical 
laboratory data, and physical examinations.
2.4 | Pharmacokinetics analysis
During the phase 1 dose-escalation part of the study, pre-dose and 
0.5, 1, 2, 4, 6, and 8 h post-dose PK samples were collected on cycle 
1 day 1 and on cycle 1 day 15; pre-dose PK samples were collected 
on cycle 1 day 2, cycle 1 day 16, cycle 2 day 1, and cycle 3 day 1. 
During the phase 1 dose-expansion part of the study, pre-dose and 
0.5, 1, 2, 4, 6, and 8 h post-dose PK samples were collected on cycle 
1 day 15 in non-NSCLC patients; pre-dose PK samples were col-
lected on cycle 1 day 16 and cycle 2 day 1. Capmatinib concentra-
tions in plasma were measured using a validated LC-MS/MS method 
with a lower limit of quantification of 1 ng/mL. Noncompartmental 
PK analysis was done to generate PK parameters of capmatinib, and 
dose proportionality of capmatinib was assessed.
2.5 | Statistical analysis
Data cutoff date for this report was July 17, 2017 when all pa-
tients had discontinued. No formal statistical power calculations 
to determine sample size were carried out for this study. It was 
estimated that a minimum of 15 subjects would be enrolled in the 
dose-escalation phase, including at least six subjects treated at the 
MTD/RP2D level. During the expansion phase, subjects with HCC, 
NSCLC, or gastric cancer were enrolled into separate groups of 
10 subjects each. Each of these three groups could be expanded 
by 15 additional subjects for a maximum of 25 subjects per group 
if additional insight into the safety and/or efficacy was desired. 
Decision for such expansion of a group was to be made no later 
than 16 weeks from initial treatment of the last subject for that 
group and by the Novartis Clinical Trial Team in consultation with 
the study investigators after reviewing all available clinical data. A 
fourth group was expected to enrol up to 15 subjects with other 
solid tumors (pRCC, GBM, and others).
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The ORR was presented by treatment group with an exact 95% 
CI if response rate of 10% or higher was observed. Kaplan-Meier es-
timate of median PFS and rate at 3, 6, and 12 months, along with 95% 
CI, were summarized by treatment group according to the investiga-
tor and BIRC. A waterfall plot of best percentage change from base-
line in sum of longest diameters according to the investigator was 
presented for each treatment group. AE were graded according to 
the Common Terminology Criteria for Adverse Events, version 4.0.
For dose-escalation, a BLRM (with two parameters) guided by the 
EWOC principle was used to make dose recommendations and to 
estimate the MTD. When the change from capsule to tablet formula-
tion was implemented, a BLRM for the tablet formulation was set up 
and used to monitor subject safety. Prior distributions for this model 
incorporated the existing dose toxicity data for capmatinib as single 
agent in both capsule and tablet formulations. The posterior distri-
butions for the risk of DLT were summarized to provide the posterior 
probability that the risk of DLT lies within the following intervals: 
[0, 0.16) underdosing, [0.16, 0.33) targeted toxicity, and [0.33, 1.00] 
excessive toxicity.
For secondary efficacy and safety endpoints, patients treated at 
the RP2D for capmatinib during the escalation phase were pooled 
with those receiving the same dosing regimen and with same dis-
ease during the expansion phase. Safety data are summarized for all 
the patients who received at least one dose of capmatinib and had 
at least one valid postbaseline safety assessment. The dose deter-
mining set consisted of all subjects from the safety set who either 
met the minimum exposure criterion (capmatinib had been given at 
the full planned daily dose for ≥21 days out of 28 days [75%] and 
the subject had sufficient safety evaluations, or had experienced a 
DLT during the first cycle). Efficacy data are summarized for all the 
patients with NSCLC who received at least one dose of capmatinib. 
PK analyses were based on data from patients in the dose-escalation 
phase and expansion phase, with at least one evaluable capmatinib 
PK profile.
TA B L E  1   Patient demographics and disease characteristics in the dose-escalation and selected dose-expansion cohorts










Age (median, y) 56.0 55.0 54.0 57.0 55.3
Age category (years), n (%)
<65 32 (84) 9 (100) 8 (73) 13 (72) 30 (79)
≥65 6 (16) 0 3 (27) 5 (28) 8 (21)
Gender (male, n [%]) 27 (71) 7 (78) 9 (82) 15 (83) 31 (82)
Race
Caucasian 6 (16) 9 (100) 6 (55) 13 (72) 28 (74)
Asian 31 (82) 0 4 (36) 1 (6) 5 (13)
Other 1 (3) 0 1 (9) 4 (22) 5 (13)
ECOG PS, n (%)
0 21 (55) 3 (33) 7 (64) 10 (56) 20 (53)
1 16 (42) 6 (67) 4 (36) 6 (33) 16 (42)
2 1 (3) 0 0 1 (6) 1 (3)
Missing 0 0 0 1 (6) 1 (3)
Primary site of cancer
Liver 15 (39) 0 11 (100) 0 11 (29)
Colon 8 (21) 0 0 0 0
Stomach 2 (5) 9 (100) 0 0 9 (24)
Lung 1 (3) 0 0 0 0
Other 12 (32) 0 0 18 (100) 18 (47)
No. of prior lines of therapy, n (%)
Missing 0 0 0 2 (11) 2 (5)
1 6 (16) 2 (22) 6 (55) 4 (22) 12 (32)
2 7 (18) 1 (11) 2 (18) 2 (11) 5 (13)
≥3 25 (66) 6 (67) 3 (27) 10 (56) 19 (50)
Abbreviations: bid, twice daily; ECOG PS, ECOG performance status; HCC, hepatocellular carcinoma; RP2D, recommended phase 2 dose.
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2.6 | Study oversight
This study was carried out in accordance with the Declaration of 
Helsinki and the principles of Good Clinical Practice. The protocol 
was approved by an Institutional Review Board at each hospital or 
site, and all patients provided written informed consent before any 
study procedures. The study was designed by the sponsor (Novartis 
Pharma AG). Data were collected and analyzed by the sponsor in 
conjunction with the authors.
3  | RESULTS
A total of 38 patients (with HCC [n = 15], colon [n = 8], gastric 
[n = 2], lung [n = 1], and other advanced solid tumor types [n = 12]) 
were enrolled into the dose-escalation part of this phase 1 study 
and 38 patients (with HCC [n = 11], gastric [n = 9], and other ad-
vanced solid tumor types [non-NSCLC; n = 18]) were enrolled into 
the expansion cohorts (Table 1). Fifty-five patients with NSCLC 
were also enrolled into an additional expansion cohort; results 
of these patients are reported separately (Schuler M et al; manu-
script submitted).
In the dose-escalation cohort, 19 of 38 (50%) patients received 
≥3 prior lines of therapy. Of the 23 evaluable patients, 26.1% had 
tumors presenting with a high level of MET gene copy gain (GCN 
≥6) and 16.7% of the 36 evaluable patients had MET-overexpressing 
tumors (IHC score 3+).
In the dose-expansion part, the majority of patients were heav-
ily pretreated, with 25 of 38 (66%) patients having received ≥3 prior 
lines of therapy. Of the patients enrolled in the selected expansion 
cohorts, where results were available (n = 31), 9.7% of patients had 
tumors presenting with high-level MET GCN and 13% of the 38 eval-
uable patients had MET-overexpressing tumors (Table 2). None of the 
patients had tumors harboring MET exon 14 skipping mutations or 
other MET mutations known to confer sensitivity to MET inhibitors.
In the escalation part, capmatinib capsules were evaluated at 
the following twice-daily (bid) doses: 100 mg (n = 4), 200 mg (n = 5), 
250 mg (n = 4), 350 mg (n = 3), 450 mg (n = 9), and 600 mg (n = 8). In 
order to improve patient compliance in reducing pill burden, a tablet 
formulation was then introduced. Capmatinib in tablet formulation 
was evaluated at the RP2D 400 mg bid (n = 5). In the dose-expan-
sion part, patients were enrolled at the RP2D of capmatinib, 600 mg 
bid, in capsule formulation. Seven patients treated with capmatinib 
in capsule formulation switched to the tablet formulation once it be-
came available.
As of July 17, 2017, all patients in the dose-escalation and se-
lected cohorts of the dose-expansion part of the study had dis-
continued treatment. Primary reason for end of treatment was 
disease progression (37 of 38 patients [97%] in the dose-escala-
tion part and 29 of 38 patients [76%] in the dose-expansion part). 
One patient discontinued as a result of AE (AST increase) in the 
dose-escalation part and six of 38 patients (16%) in the dose-ex-
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1], nausea/vomiting [n = 1], nausea/dizziness [n = 1], pneumonia 
[n = 1], and peripheral edema [n = 1]). Reasons for discontinuation 
for the remaining patients in the selected cohorts of the dose-ex-
pansion part were consent withdrawal (2 patients) and protocol 
deviation (1 patient). No patients discontinued as a result of death 
in either part of the study.
3.1 | Dose determination
Starting dose for dose escalation of this study was 100 mg bid as cap-
sules. The bid regimen was selected based on the half-life of capmatinib 
(3.5-6.3 h) and in order to maintain capmatinib concentrations above 
the EC90 (90% inhibition of c-MET phosphorylation in animal models) 
for p-MET inhibition in c-MET-dependent mouse tumor models (EC90 
~71 nmol/L, total concentration).30 Across the six bid dose levels ex-
plored in the capsule formulation, DLT occurred at 200 mg bid (grade 
3 fatigue in 1 patient), 250 mg bid (grade 3 bilirubin increased in 1 
patient), and 450 mg bid (grade 3 fatigue in 1 patient). No DLT were ob-
served at the 600-mg bid capsule dose level. Based on the BLRM used 
to guide dose escalation, posterior probability of excessive toxicity was 
20.1% for the 600 mg bid dose level in the dose-escalation phase (ie, 
<25% chance that the true DLT rate was ≥33%). No DLT was observed 
among patients treated with the tablet at the 400 mg bid dose. MTD 
was not reached. Capmatinib tablets at 400 mg bid had comparable 
tolerability and exposure to that of 600 mg bid capsules. Capmatinib 
400 mg bid tablets or 600 mg bid capsules were selected as the RP2D, 
a dose at which Ctrough >EC90 (90% inhibition of c-MET phosphoryla-
tion in animal models) is expected to be achieved and maintained.
3.2 | Safety
The most frequent AE (all grades, >30%) in the dose-escalation part re-
gardless of causality were decreased appetite (42%), peripheral edema 
(40%), vomiting (40%), and nausea (37%) (Table S2). The most frequent 
grade 3 or 4 AE (>5%) regardless of causality were increase in levels 
of blood bilirubin (11%), fatigue (8%), and AST increase (8%). The most 
common AE (all grades, >20%) suspected to be study drug-related 
were nausea (32%), decreased appetite (29%), vomiting (29%), fatigue 
(26%), and peripheral edema (21%) (Table 3). Study drug-related grade 
3 or 4 AE were rare. The most commonly reported AE were fatigue 
(8%), ALT increase, and hypophagia (both 5%).
In the selected cohorts of the dose-expansion part of the study, 
the most frequent AE (all grades, >30%) regardless of causality were 
nausea (42%), peripheral edema (39%), and fatigue (34%) (Table S2).
The most frequent grade 3 or 4 AE regardless of causality were fa-
tigue (8%), nausea, AST increase, anemia, ascites, bilirubin increase, 
constipation, and ALT increase (all 5%).
Nausea (29%), peripheral edema (26%), and fatigue (24%) were 
the most common AE suspected to be study drug-related (Table 3). 
ALT and lipase increases were the most commonly reported grade 3 
or 4 AE suspected to be study drug-related (both 5%).
3.3 | Efficacy
Efficacy was reported according to the investigator’s assessment. 
In the dose-escalation part of the study, at the data cutoff date of 
July 17, 2017, stable disease was reported in 10 of 38 (26%) patients 
(Table 4). In the dose-escalation part, tumor shrinkage was observed 
in two patients (colon cancer and HCC) treated at 450 mg bid (cap-
sule) dose level.
Efficacy results in the expansion cohorts of patients with gas-
tric cancer, HCC, and other solid tumors (non-NSCLC including GBM 
and pRCC) are presented in Table 4. In these cohorts, stable disease 
was reported in two of nine (22%) patients with gastric cancer, five 
of 11 (46%) patients with HCC, and five of 18 (28%) patients with 
other advanced solid tumor types. Tumor reduction was reported in 
a number of patients; of note, two other solid tumor patients with 
GCN ≥6 achieved substantial tumor reduction (Figure 1). Duration 
of response for evaluable patients by disease cohorts is shown in 
Figure S1.
3.4 | Pharmacokinetics analysis
Capmatinib was rapidly absorbed after oral dose, with median time 
to peak plasma concentration (Tmax) ranging from 1 to 4 h for cap-
sules and approximately 2 h for tablets following single and multiple 
doses (Table 5).
Steady-state AUCtau and Cmax of capmatinib were generally dose 
proportional across the dose range from 100 to 600 mg bid for the 
capsules (Table 5). The drug accumulation ratio following multiple 
doses generally ranged from one- to twofold for the capsules, with 
more accumulation observed at 450 and 600 mg bid (ca. twofold). 
Limited drug accumulation was observed with 400 mg bid tablets 
(Table 6).
Tablet formulation at 400 mg bid provided comparable mean ex-
posures to the capsules at 600 mg bid (Table 5). Mean (mean CV%) 
steady-state exposure of capmatinib at the RP2D (tablet 400 mg bid) 
was 22 000 (35.5%) h*ng/mL for AUC0–12 h,ss and 4910 (51.0%) ng/
mL for Cmax,ss (n = 8).
3.5 | Pharmacodynamic data
Capmatinib PD activity in inhibiting the MET pathway was shown in 
paired biopsies collected from a patient with advanced CRC. Near-
complete p-MET inhibition (as determined by IHC; H-score = 2) was 
shown following capmatinib at 450 mg bid in capsule formulation at 
cycle 1 day 15 (Figure S2).
4  | DISCUSSION
Capmatinib was well tolerated with a manageable safety profile 
across all explored doses. Only three DLT were reported, one each 
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at 200 mg bid, 250 mg bid, and 450 mg bid doses. No DLT were 
observed at the 600-mg bid capsule dose level. Based on the BLRM 
used to guide dose escalation, the posterior probability of excessive 
toxicity was 20.1% for the 600-mg bid dose level in the dose-escala-
tion phase. Capmatinib exposure was found to increase by dose up 
to 600 mg bid dose level.
In the dose-escalation part, tumor shrinkage was observed for 
two patients (colon cancer and HCC) treated with the 450-mg bid 
(capsule) dose level. Near-complete PD effect (defined as p-MET in-
hibition) was observed in this patient with colorectal cancer at 450-
mg bid capsule dose level. MTD was not reached. Thus, based on 
considerations of the estimated MTD by the BLRM model along with 
overall assessment of safety, PK and PD results, and preliminary clin-
ical efficacy data, the RP2D was determined initially to be 600 mg 
bid in capsule formulation.
In order to improve patient compliance reducing the pill burden, a 
tablet formulation was introduced, as 12 capsules had to be taken bid as 
the 600 mg bid dose regimen. Relative bioavailability of INC280 tablet 
with respect to capsule formulation was assessed in healthy subjects, 
and a tablet safety cohort at 400 mg bid was further evaluated in this 
study. The evaluated tablet formulation at a dose of 400 mg bid was well 
tolerated with no DLT reported, had a comparable favorable safety pro-
file, and comparable mean exposure to the capsule formulation at a dose 
of 600 mg bid. Thus, the RP2D was determined to be 400 mg bid in tab-
let formulation. A number of the expansion-part patients were switched 
from the capsule formulation to the tablet as soon as it was available.
Overall, capmatinib was well tolerated at the RP2D (600 mg bid 
capsule and 400 mg bid tablet). The most common AE suspected to 
be related to the study drug were mostly grade 1 or 2.
Only a limited number of patients were determined to have tumors 
harboring high-level MET gene copy gain or high MET overexpression or 
MET mutations in both the escalation and selected expansion cohorts. 
Although the best overall response was limited with stable disease in 26% 
of escalation patients and in 32% of the expansion patients (22% of pa-
tients in the gastric cancer cohort, 46% of patients in the HCC cohort, 
and 28% of patients with other advanced solid tumor types), a number of 
these patients achieved substantial tumor reduction and durable stable 
disease; of note, two other solid tumor patients with GCN ≥6 achieved 
substantial tumor reduction (Figure 1). These results were similar to those 
observed with capmatinib with Japanese patients with advanced solid 
tumors, where the best overall response was stable disease (reported in 
18.2% of patients).34 BOI-9016M, a novel c-MET inhibitor, showed activ-
ity in Chinese patients with advanced solid tumors, with partial response in 
one (5%) of 20 patients and stable disease in 10 (50%) patients.35 Results 
for other MET inhibitors have been reported in molecularly selected pa-
tients with NSCLC. Crizotinib, a multikinase (ALK/ROS1/MET) inhibitor, 
showed clinically meaningful antitumor activity in patients with MET exon 
14-mutated NSCLC, with an ORR of 32% (21 of 65 patients; 95% CI: 21-
45)36 and in patients with high MET amplification (MET/CEP7 ≥4) status, 
with an ORR of 40% (eight of 20 patients; 95% CI: 19.1-63.9).37 Tepotinib, 
a selective MET inhibitor, showed activity with an ORR of 57.5% (23 of 40 
patients; 95% CI: 40.9-73.0) by the investigator in patients with advanced 
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F I G U R E  1   Best percentage change from baseline in sum of tumor diameters according to investigator assessment in dose-expansion 
cohorts (N = 18)*. *Patients with measurable baseline disease and at least one valid postbaseline (BIRC) assessment (best percentage change 
from baseline <0 [n = 7] and >0 [n = 11]). 


























































































































TA B L E  5   Summary of steady-state PK parameters for capmatinib
PK parameter
(Cycle 1, Day 15)
















Mean (SD) 3820 (2420) 13 500 (6530) 7070 (3990) 19 400 (5360) 18 800 (6870) 25 600 (14 900) 22 000 (7790)
CV% mean 63.5 48.5 56.4 27.7 36.6 58.3 35.5
Cmax (ng/mL)
Mean (SD) 660 (550) 2500 (856) 1580 (1010) 4410 (3800) 3200 (1280) 4890 (3580) 4910 (2510)
CV% mean 83.3 34.2 63.8 86.3 39.8 73.2 51.0
Tmax (h)
Median 2.86 1.92 1.00 3.93 2.00 2.00 2.02
 (Min; Max) (1.88; 4.00) (1.85; 8.00) (0.45; 2.02) (1.00; 4.02) (1.83; 7.87) (0.517; 8.42) (0.50; 4.33)
Abbreviations: AUC0–12 h, area under concentration-time curve from time 0 to 12 h; bid, twice daily; Cmax, maximum observed plasma concentration; 
CV%, percent coefficient of variation; Tmax, median time to peak plasma concentration; PK, pharmacokinetics.
TA B L E  6   Summary of accumulation ratio for capmatinib following repeated dosage
PK parameter
(Cycle 1, Day 15)
















Mean (SD) 1.54 (0.786) 1.36 (0.869) 1.08 (0.443) 1.38 (0.614) 2.36 (1.75) 2.07 (0.848) 1.09 (0.408)
CV% mean 50.9 63.9 40.8 44.5 74.0 40.9 37.6
Abbreviations: bid, twice daily; CV%, percent coefficient of variation; PK, pharmacokinetics; Racc, mean accumulation ratio; ss, at steady state.
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Overall, in the present study, suboptimal molecular selection for 
MET status might have contributed to the limited efficacy observed 
in both the escalation and the expansion cohorts of patients with 
gastric cancer, HCC, and other solid tumors.
Results of the expansion part of the study conducted with cap-
matinib at the RP2D in patients with advanced MET-dependent 
NSCLC, including a subset of patients enrolled with more stringently 
specified MET dysregulation biomarker criteria, are reported sepa-
rately (Schuler M et al; manuscript submitted). Further, the predic-
tive value of different mechanisms of MET dysregulation (including 
MET amplification and METΔex14 mutation) in advanced NSCLC is 
prospectively being explored in another ongoing phase 2 study of 
capmatinib (NCT02414139).
In summary, the RP2D of capmatinib was 600 mg bid capsule or 
400 mg bid tablet. The tablet formulation is now used in all capma-
tinib studies. Capmatinib was well tolerated and showed antitumor 
activity and acceptable safety profile at the R2PD.
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